

ADAR1 Activation Drives Leukemia Stem Cell Self-Rene

Cell Stem Cell

19, 177-191

DOI: [10.1016/j.stem.2016.05.004](https://doi.org/10.1016/j.stem.2016.05.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	RNA editing as an activator of self-renewal in cancer. <i>Stem Cell Investigation</i> , 2016, 3, 68-68.	1.3	1
2	Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. <i>Genes</i> , 2016, 7, 129.	1.0	58
3	ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity. <i>Cell Stem Cell</i> , 2016, 19, 141-142.	5.2	9
4	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. <i>Cell Stem Cell</i> , 2016, 19, 599-612.	5.2	97
5	Emerging RNA editing biomarkers will foster drug development. <i>Drug Discovery Today</i> , 2017, 22, 1056-1063.	3.2	6
6	RNA editing-dependent epitranscriptome diversity in cancer stem cells. <i>Nature Reviews Cancer</i> , 2017, 17, 381-392.	12.8	86
7	RNA editing signature during myeloid leukemia cell differentiation. <i>Leukemia</i> , 2017, 31, 2824-2832.	3.3	29
8	Bad blood promotes tumour progression. <i>Nature</i> , 2017, 549, 465-466.	13.7	4
9	ADAR RNA editing in human disease; more to it than meets the I. <i>Human Genetics</i> , 2017, 136, 1265-1278.	1.8	110
10	<i>miR-99</i> regulates normal and malignant hematopoietic stem cell self-renewal. <i>Journal of Experimental Medicine</i> , 2017, 214, 2453-2470.	4.2	44
11	Alu-dependent RNA editing of <i>GLI1</i> promotes malignant regeneration in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 1922.	5.8	89
12	Impact of RNA Modifications and RNA-Modifying Enzymes on Eukaryotic Ribonucleases. <i>The Enzymes</i> , 2017, 41, 299-329.	0.7	11
13	RNA Editing in Pathogenesis of Cancer. <i>Cancer Research</i> , 2017, 77, 3733-3739.	0.4	60
14	RNA Editing, ADAR1, and the Innate Immune Response. <i>Genes</i> , 2017, 8, 41.	1.0	36
15	MotomiRs: miRNAs in Motor Neuron Function and Disease. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 127.	1.4	26
16	Protein recoding by ADAR1-mediated RNA editing is not essential for normal development and homeostasis. <i>Genome Biology</i> , 2017, 18, 166.	3.8	64
17	Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. <i>Genome Biology</i> , 2017, 18, 205.	3.8	161
18	Deciphering the Epitranscriptome in Cancer. <i>Trends in Cancer</i> , 2018, 4, 207-221.	3.8	39

#	ARTICLE	IF	CITATIONS
19	LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. <i>Oncogene</i> , 2018, 37, 2746-2756.	2.6	16
20	ADAR1 prevents small intestinal injury from inflammation in a murine model of sepsis. <i>Cytokine</i> , 2018, 104, 30-37.	1.4	10
21	When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference. <i>BioEssays</i> , 2018, 40, 1700188.	1.2	35
22	Human cancer tissues exhibit reduced A-to-I editing of miRNAs coupled with elevated editing of their targets. <i>Nucleic Acids Research</i> , 2018, 46, 71-82.	6.5	138
23	ADARs and editing: The role of A-to-I RNA modification in cancer progression. <i>Seminars in Cell and Developmental Biology</i> , 2018, 79, 123-130.	2.3	80
24	The role of A-to-I RNA editing in cancer development. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 51-56.	1.5	67
25	The Role of RNA Editing in Cancer Development and Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2018, 9, 762.	1.5	70
26	RNA-sequencing analysis of umbilical cord plasma microRNAs from healthy newborns. <i>PLoS ONE</i> , 2018, 13, e0207952.	1.1	8
27	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	0.7	36
28	CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 73, 38-44.	0.6	48
29	All I's on the <sc>RADAR</sc>: role of <sc>ADAR</sc> in gene regulation. <i>FEBS Letters</i> , 2018, 592, 2860-2873.	1.3	31
30	Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. <i>Cell Stem Cell</i> , 2018, 22, 951-959.e3.	5.2	120
31	Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. <i>Blood</i> , 2018, 132, 1304-1317.	0.6	67
32	CRISPR-Cas13 Precision Transcriptome Engineering in Cancer. <i>Cancer Research</i> , 2018, 78, 4107-4113.	0.4	66
33	TGF- β 2 induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , 2018, 9, 1845.	5.8	101
34	ADAR1 attenuates allogeneic graft rejection by suppressing miR-21 biogenesis in macrophages and promoting M2 polarization. <i>FASEB Journal</i> , 2018, 32, 5162-5173.	0.2	25
35	Post-transcriptional regulation in hematopoiesis: RNA binding proteins take control. <i>Biochemistry and Cell Biology</i> , 2019, 97, 10-20.	0.9	28
36	MicroRNA let-7-TGFB3 signalling regulates cardiomyocyte apoptosis after infarction. <i>EBioMedicine</i> , 2019, 46, 236-247.	2.7	30

#	ARTICLE	IF	CITATIONS
37	ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1763.	2.2	137
38	A genome-wide <i>scRNA</i> screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e9930.	3.3	27
39	A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. <i>Blood</i> , 2019, 134, 1960-1972.	0.6	38
40	RNA-modifying enzymes and their function in a chromatin context. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 858-862.	3.6	24
41	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2019, 33, 1543-1556.	3.3	127
42	AKT-dependent phosphorylation of the adenosine deaminases ADAR1 and 2 inhibits deaminase activity. <i>FASEB Journal</i> , 2019, 33, 9044-9061.	0.2	20
43	RNA Biology Provides New Therapeutic Targets for Human Disease. <i>Frontiers in Genetics</i> , 2019, 10, 205.	1.1	42
44	<i>Let-7</i> as biomarker, prognostic indicator, and therapy for precision medicine in cancer. <i>Clinical and Translational Medicine</i> , 2019, 8, 24.	1.7	172
45	Deciphering miRNAs™ Action through miRNA Editing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6249.	1.8	518
46	Defining the functions of adenosine-to-inosine RNA editing through hematology. <i>Current Opinion in Hematology</i> , 2019, 26, 241-248.	1.2	6
47	microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6094.	1.8	20
48	Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6141.	1.8	63
49	Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase “ chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 805-811.	0.6	4
50	Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries. <i>Nucleic Acids Research</i> , 2019, 47, e22-e22.	6.5	23
51	ADAR1 Editing and its Role in Cancer. <i>Genes</i> , 2019, 10, 12.	1.0	71
52	Epigenetics of Lupus. , 2019, , 69-85.		0
53	The adaptive potential of RNA editing-mediated miRNA-retargeting in cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 291-300.	0.9	15
54	Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. <i>Cancer Cell</i> , 2019, 35, 81-94.e7.	7.7	64

#	ARTICLE	IF	CITATIONS
55	Large-scale prediction of ADAR-mediated effective human A-to-I RNA editing. <i>Briefings in Bioinformatics</i> , 2019, 4, 102-109.	3.2	11
56	RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications. <i>Annual Review of Cancer Biology</i> , 2020, 4, 221-240.	2.3	60
57	Non-Coding RNA Editing in Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 1845.	1.7	16
58	Identification of genetic variants controlling RNA editing and their effect on RNA structure stabilization. <i>European Journal of Human Genetics</i> , 2020, 28, 1753-1762.	1.4	5
59	The cGAS-STING Pathway in Hematopoiesis and Its Physiopathological Significance. <i>Frontiers in Immunology</i> , 2020, 11, 573915.	2.2	17
60	Stem cell programs in cancer initiation, progression, and therapy resistance. <i>Theranostics</i> , 2020, 10, 8721-8743.	4.6	208
61	What do editors do? Understanding the physiological functions of A-to-I RNA editing by adenosine deaminase acting on RNAs. <i>Open Biology</i> , 2020, 10, 200085.	1.5	31
62	Epitranscriptomics in Normal and Malignant Hematopoiesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6578.	1.8	3
63	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 193.	7.1	66
64	The p150 Isoform of ADAR1 Blocks Sustained RLR signaling and Apoptosis during Influenza Virus Infection. <i>PLoS Pathogens</i> , 2020, 16, e1008842.	2.1	22
65	ADAR1-Dependent RNA Editing Promotes MET and iPSC Reprogramming by Alleviating ER Stress. <i>Cell Stem Cell</i> , 2020, 27, 300-314.e11.	5.2	22
66	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	2.6	30
67	Epitranscriptomics in Hematopoiesis and Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2020, 1, 26-31.	2.6	18
68	ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. <i>Oncogene</i> , 2020, 39, 3738-3753.	2.6	60
69	Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology. <i>Molecular Cancer</i> , 2020, 19, 64.	7.9	69
70	The epitranscriptome landscape of small noncoding RNAs in stem cells. <i>Stem Cells</i> , 2020, 38, 1216-1228.	1.4	12
71	Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. <i>Science Advances</i> , 2020, 6, eaba5136.	4.7	29
72	mRNA modification orchestrates cancer stem cell fate decisions. <i>Molecular Cancer</i> , 2020, 19, 38.	7.9	31

#	ARTICLE	IF	CITATIONS
73	Writers, readers and erasers of RNA modifications in cancer. <i>Cancer Letters</i> , 2020, 474, 127-137.	3.2	104
74	AKT-Dependent Phosphorylation of ADAR1p110 and ADAR2 Represents a New and Important Link Between Cell Signaling and RNA Editing. <i>DNA and Cell Biology</i> , 2020, 39, 343-348.	0.9	6
75	Post-Transcriptional Regulation of Homeostatic, Stressed, and Malignant Stem Cells. <i>Cell Stem Cell</i> , 2020, 26, 138-159.	5.2	54
76	An internal deletion of ADAR rescued by MAVS deficiency leads to a minute phenotype. <i>Nucleic Acids Research</i> , 2020, 48, 3286-3303.	6.5	39
77	Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development. <i>Experimental and Molecular Medicine</i> , 2020, 52, 582-593.	3.2	10
78	Differential Alternative Polyadenylation Landscapes Mediate Hematopoietic Stem Cell Activation and Regulate Glutamine Metabolism. <i>Cell Stem Cell</i> , 2020, 26, 722-738.e7.	5.2	32
79	Role of RNA modifications in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 303-322.	12.8	621
80	Targeting RNA-binding proteins in acute and chronic leukemia. <i>Leukemia</i> , 2021, 35, 360-376.	3.3	18
81	The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. <i>Molecular Oncology</i> , 2021, 15, 262-278.	2.1	18
82	ADARs, RNA editing and more in hematological malignancies. <i>Leukemia</i> , 2021, 35, 346-359.	3.3	10
84	Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. <i>Cell Reports</i> , 2021, 34, 108670.	2.9	22
85	Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 581.	1.8	31
86	ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. <i>Genome Biology</i> , 2021, 22, 51.	3.8	71
87	The effects of RNA editing in cancer tissue at different stages in carcinogenesis. <i>RNA Biology</i> , 2021, 18, 1-16.	1.5	15
88	MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR. <i>Experimental Hematology and Oncology</i> , 2021, 10, 8.	2.0	12
89	The non-coding epitranscriptome in cancer. <i>Briefings in Functional Genomics</i> , 2021, 20, 94-105.	1.3	11
90	A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects. <i>Frontiers in Oncology</i> , 2020, 10, 632187.	1.3	17
91	Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter. <i>Frontiers in Oncology</i> , 2021, 11, 650473.	1.3	16

#	ARTICLE	IF	CITATIONS
92	Construction of a microRNA-mRNA Regulatory Network in <i>De Novo</i> Cytogenetically Normal Acute Myeloid Leukemia Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 199-210.	0.3	4
93	Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. <i>Cell Stem Cell</i> , 2021, 28, 623-636.e9.	5.2	29
94	let-7 microRNAs: Their Role in Cerebral and Cardiovascular Diseases, Inflammation, Cancer, and Their Regulation. <i>Biomedicines</i> , 2021, 9, 606.	1.4	40
95	The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance. <i>Current Cancer Drug Targets</i> , 2021, 21, 326-352.	0.8	23
97	RNA modifications in hematopoietic malignancies: a new research frontier. <i>Blood</i> , 2021, 138, 637-648.	0.6	24
98	The role of <i>RNA</i> editing enzyme ADAR1 in human disease. <i>Wiley Interdisciplinary Reviews RNA</i> , 2022, 13, e1665.	3.2	61
99	Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7093.	1.8	19
100	Epitranscriptomics: A New Layer of microRNA Regulation in Cancer. <i>Cancers</i> , 2021, 13, 3372.	1.7	16
101	Hepatitis B virus evades immune recognition via RNA adenosine deaminase ADAR1-mediated viral RNA editing in hepatocytes. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1871-1882.	4.8	26
102	<i>RNA</i> editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating <i>CX3CR1</i> fractalkine expression. <i>Drug Development Research</i> , 2022, 83, 328-338.	1.4	6
103	The Role of microRNA Let-7d in Female Malignancies and Diseases of the Female Reproductive Tract. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7359.	1.8	12
104	Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer. <i>British Journal of Pharmacology</i> , 2022, 179, 2868-2889.	2.7	19
105	High-throughput screening to identify potential inhibitors of the Z ^{1±} domain of the adenosine deaminase 1 (ADAR1). <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 6297-6304.	1.8	6
106	Recent progress on targeting leukemia stem cells. <i>Drug Discovery Today</i> , 2021, 26, 1904-1913.	3.2	7
107	Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia. <i>Blood</i> , 2022, 139, 424-438.	0.6	11
108	Roles of miR-432 and circ_0000418 in mediating the anti-depressant action of ADAR1. <i>Neurobiology of Stress</i> , 2021, 15, 100396.	1.9	4
109	CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia. <i>Molecular Biology</i> , 2021, 55, 121-132.	0.4	1
110	Adenosine-to-Inosine RNA Editing: A Key RNA Processing Step Rewriting Transcriptome in Normal Physiology and Diseases. , 2021, , 133-151.		0

#	ARTICLE	IF	CITATIONS
111	G Protein-Coupled Receptor GPR87 Promotes the Expansion of PDA Stem Cells through Activating JAK2/STAT3. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 384-393.	2.0	10
112	Non-coding RNA networks in cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 5-18.	12.8	1,359
113	Genome-Wide Characterization of RNA Editing Sites in Primary Gastric Adenocarcinoma through RNA-seq Data Analysis. <i>International Journal of Genomics</i> , 2020, 2020, 1-16.	0.8	4
114	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	2.6	1
115	ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications. <i>Annals of Translational Medicine</i> , 2019, 7, 686-686.	0.7	13
116	A NEW VIEW OF GENETIC MUTATIONS. <i>Australasian Medical Journal</i> , 2017, 10, .	0.1	7
117	Emerging role of let-7 family in the pathogenesis of hematological malignancies. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112334.	2.5	14
119	Functional categories of RNA regulation. , 2020, , 59-83.		0
120	8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR. <i>Cancer Research Communications</i> , 2021, 1, 56-64.	0.7	11
121	The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. <i>American Journal of Cancer Research</i> , 2020, 10, 148-163.	1.4	10
122	Upping the antizyme: AZIN1 directs stem cell fate. <i>Blood</i> , 2021, 138, 1910-1911.	0.6	1
124	Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells. <i>Annual Review of Medicine</i> , 2022, 73, 307-320.	5.0	5
125	Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. <i>F1000Research</i> , 0, 10, 1288.	0.8	1
126	Adenosine-to-Inosine RNA Editing and <i>N⁶</i> -Methyladenosine Modification Modulating Expression of Drug Metabolizing Enzymes. <i>Drug Metabolism and Disposition</i> , 2022, 50, 624-633.	1.7	5
127	ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
128	The emerging roles of circRNAs in cancer and oncology. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 188-206.	12.5	387
129	A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2344-2355.	1.7	6
130	RNA Editing in Glioma as a Sexually Dimorphic Prognostic Factor That Affects mRNA Abundance in Fatty Acid Metabolism and Inflammation Pathways. <i>Cells</i> , 2022, 11, 1231.	1.8	0

#	ARTICLE	IF	CITATIONS
131	Self or Non-Self? It Is also a Matter of RNA Recognition and Editing by ADAR1. <i>Biology</i> , 2022, 11, 568.	1.3	4
132	Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion. <i>Molecular Cancer Research</i> , 2022, 20, 960-971.	1.5	8
133	Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. <i>F1000Research</i> , 2021, 10, 1288.	0.8	5
134	Chronic myeloid leukemia stem cells: targeting therapeutic implications. <i>Stem Cell Research and Therapy</i> , 2021, 12, 603.	2.4	27
135	Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells. <i>Journal of Clinical Medicine</i> , 2021, 10, 5805.	1.0	7
136	ADAR1 and its implications in cancer development and treatment. <i>Trends in Genetics</i> , 2022, 38, 821-830.	2.9	33
137	ADAR1 Prevents R-loop Accumulation-Driven ATR Pathway Activation in Ovarian Cancer. <i>Journal of Cancer</i> , 2022, 13, 2397-2412.	1.2	8
138	Interplay between A-to-I Editing and Splicing of RNA: A Potential Point of Application for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5240.	1.8	9
140	Epitranscriptomics in myeloid malignancies. <i>Blood Science</i> , 0, Publish Ahead of Print, .	0.4	0
141	ADAR1-Mediated RNA Editing and Its Role in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	9
142	Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. <i>Biomedicines</i> , 2022, 10, 1841.	1.4	2
143	Unifying Different Cancer Theories in a Unique Tumour Model: Chronic Inflammation and Deaminases as Meeting Points. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8720.	1.8	1
144	Let-7 as a Promising Target in Aging and Aging-Related Diseases: A Promise or a Pledge. <i>Biomolecules</i> , 2022, 12, 1070.	1.8	8
145	ADAR1 Isoforms Regulate Let-7d Processing in Idiopathic Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9028.	1.8	3
146	Targeting purine metabolism in ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	22
147	Identification and analysis of microRNA editing events in recurrent bladder cancer based on RNA sequencing: MicroRNA editing level is a potential novel biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
148	RNA modifications: importance in immune cell biology and related diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	74
149	CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies. <i>Oncogene</i> , 2022, 41, 4591-4605.	2.6	4

#	ARTICLE	IF	CITATIONS
150	Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance. International Journal of Molecular Sciences, 2022, 23, 12271.	1.8	3
151	RNA binding proteins in MLL-rearranged leukemia. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
152	Identification of microRNA editing sites in three subtypes of leukemia. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
153	The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF- κ B1 p105 to p50. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	2
155	The Repertoire of RNA Modifications Orchestrates a Plethora of Cellular Responses. International Journal of Molecular Sciences, 2023, 24, 2387.	1.8	4
157	<i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target. Blood Cancer Discovery, 2023, 4, 180-207.	2.6	2
158	Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell Stem Cell, 2023, 30, 250-263.e6.	5.2	10
159	Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. Cell Reports Medicine, 2023, 4, 100962.	3.3	8
160	Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits. Life Sciences, 2023, 323, 121592.	2.0	1
161	The cellular and KSHV A-to-I RNA editome in primary effusion lymphoma and its role in the viral lifecycle. Nature Communications, 2023, 14, .	5.8	5
162	RNA modifications in hematological malignancies. International Journal of Hematology, 2023, 117, 807-820.	0.7	2
163	Three-Step Synthetic Pathway toward Fully Decorated [1,2,3]Triazolo[4,5- <i>d</i>]pyrimidine (8-Azapurine) Derivatives. Organic Letters, 2023, 25, 2820-2824.	2.4	3
164	RNA modifications in cancer. British Journal of Cancer, 2023, 129, 204-221.	2.9	19
175	RNA modification: mechanisms and therapeutic targets. Molecular Biomedicine, 2023, 4, .	1.7	9
178	RNA modification in cardiovascular disease: implications for therapeutic interventions. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	0
179	RNA Modifications in Cancer Stem Cell Biology. Cancer Treatment and Research, 2023, , 25-47.	0.2	0